Researchers at the University of Maryland Medical Center are developing a stem cell treatment that can be utilized to treat hypoplastic left heart syndrome (HLHS) in children. By taking a new approach to make the right side of the heart stronger instead of replacing the damaged left side, researchers hope to engender a more permanent fix. The procedure would represent a significant advancement over current HLHS treatments; which include heart transplants and reconstructive procedures that only provide temporary relief.
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease, stemsaveblog
- Pediatric Congenital Heart Disease patient
The Mayo Clinic recently announced the first stem cell based clinical trial for treating pediatric congenital heart disease in the US. The stem cell therapy seeks to treat hypoplastic left heart syndrome (HLHS), a rare defect in which the left side of the heart is critically underdeveloped. The treatment utilizes patient’s own [autologous] stem cells taken from the child’s umbilical cord blood.